A PSE approach to patient-individualized physiologically-based pharmacokinetic modeling

Abstract Pharmacokinetic modeling allows predicting the drug concentration reached in the blood as a consequence of a specific administration. When such models are based on mammalian anatomy and physiology it is possible to theoretically evaluate the drug concentration in every organ and tissue of the body. This is the case of the so-called physiologically based pharmacokinetic (PBPK) models. This paper proposes and validates a procedure to deploy PBPK models based on a simplified, although highly consistent with human anatomy and physiology, approach. The article aims at reducing the pharmacokinetic variations among subjects due to inter-individual variability, by applying a strategy to individualize some model parameters. The simulation results are validated respect to experimental data on remifentanil.

[1]  Malcolm Rowland,et al.  Lumping of Whole-Body Physiologically Based Pharmacokinetic Models , 1998, Journal of Pharmacokinetics and Biopharmaceutics.

[2]  R. J. Lutz,et al.  A review of the applications of physiologically based pharmacokinetic modeling , 1979, Journal of Pharmacokinetics and Biopharmaceutics.

[3]  G. Giaccone,et al.  Population pharmacokinetic analysis of sorafenib in patients with solid tumours. , 2011, British journal of clinical pharmacology.

[4]  Beatrice Perissutti,et al.  A physiologically-oriented mathematical model for the description of in vivo drug release and absorption , 2014 .

[5]  M. Delp,et al.  Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.

[6]  L. Achenie,et al.  An advanced model for controlled oral drug delivery , 2012 .

[7]  Gaetano Lamberti,et al.  Physiologically Based Pharmacokinetics: A Simple, All Purpose Model , 2010 .

[8]  Rakesh K. Jain,et al.  Kinetics of uptake, distribution, and excretion of zinc in rats , 1981, Annals of Biomedical Engineering.

[9]  David J. Hermann,et al.  The Pharmacokinetics of the New Short‐acting Opioid Remifentanil (GI87084B) in Healthy Adult Male Volunteers , 1993, Anesthesiology.

[10]  Lawrence X. Yu,et al.  Compartmental transit and dispersion model analysis of small intestinal transit flow in humans , 1996 .

[11]  Gürkan Sin,et al.  First principles pharmacokinetic modeling: A quantitative study on Cyclosporin , 2013, Comput. Chem. Eng..

[12]  S. Lindstedt,et al.  Use of allometry in predicting anatomical and physiological parameters of mammals , 2002, Laboratory animals.

[13]  G L Amidon,et al.  Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. , 1996, Advanced drug delivery reviews.

[14]  B Agoram,et al.  Predicting the impact of physiological and biochemical processes on oral drug bioavailability. , 2001, Advanced drug delivery reviews.

[15]  Luke E. K. Achenie,et al.  A mechanistic approach for modeling oral drug delivery , 2013, Comput. Chem. Eng..

[16]  Malcolm Rowland,et al.  Reducing Whole Body Physiologically Based Pharmacokinetic Models Using Global Sensitivity Analysis: Diazepam Case Study , 2006, Journal of Pharmacokinetics and Pharmacodynamics.

[17]  Gintaras V. Reklaitis,et al.  Postulating Compartmental Models Using a Flexible Approach , 2014 .

[18]  H. H. Borgstedt,et al.  Tissue weights and rates of blood flow in man for the prediction of anesthetic uptake and distribution. , 1971, Anesthesiology.

[19]  Davide Manca,et al.  Definition and validation of a patient-individualized physiologically-based pharmacokinetic model , 2016, Comput. Chem. Eng..

[20]  Gaetano Lamberti,et al.  Modeling the pharmacokinetics of extended release pharmaceutical systems , 2009 .

[21]  R. Leggett,et al.  Reference values for resting blood flow to organs of man. , 1989, Clinical physics and physiological measurement : an official journal of the Hospital Physicists' Association, Deutsche Gesellschaft fur Medizinische Physik and the European Federation of Organisations for Medical Physics.

[22]  K T Muir,et al.  Pharmacokinetics of Remifentanil (GI87084B) and Its Major Metabolite (GI90291) in Patients Undergoing Elective Inpatient Surgery , 1993, Anesthesiology.

[23]  H Derendorf,et al.  Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. , 1997, International journal of clinical pharmacology and therapeutics.